Senzime Future Growth

Future criteria checks 2/6

Senzime is forecast to grow earnings and revenue by 75.2% and 71.9% per annum respectively. EPS is expected to grow by 77.4% per annum. Return on equity is forecast to be -4.9% in 3 years.

Key information

75.2%

Earnings growth rate

77.4%

EPS growth rate

Medical Equipment earnings growth	17.1%
Revenue growth rate	71.9%
Future return on equity	-4.9%
Analyst coverage	Low
Last updated	15 Nov 2024

Recent future growth updates

Recent updates

Earnings and Revenue Growth Forecasts

OTCPK:SNZZ.F - Analysts future estimates and past financials data (SEK Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	277	1	2	30	3
12/31/2025	149	-62	-51	-33	3
12/31/2024	66	-120	-125	-108	2
9/30/2024	55	-131	-129	-113	N/A
6/30/2024	47	-130	-125	-113	N/A
3/31/2024	41	-131	-119	-110	N/A
12/31/2023	36	-134	-122	-114	N/A
9/30/2023	29	-138	-121	-114	N/A
6/30/2023	24	-137	-164	-158	N/A
3/31/2023	19	-143	-159	-153	N/A
12/31/2022	14	-133	-142	-137	N/A
9/30/2022	13	-114	-133	-128	N/A
6/30/2022	11	-104	-86	-80	N/A
3/31/2022	12	-86	-84	-80	N/A
12/31/2021	11	-82	-84	-81	N/A
9/30/2021	11	-74	-78	-76	N/A
6/30/2021	11	-66	-65	-64	N/A
3/31/2021	8	-56	-50	-50	N/A
12/31/2020	9	-47	-39	-38	N/A
9/30/2020	9	-41	-31	-30	N/A
6/30/2020	9	-36	-25	-23	N/A
3/31/2020	9	-32	-25	-22	N/A
12/31/2019	7	-33	-30	-27	N/A
9/30/2019	7	-34	-29	-25	N/A
6/30/2019	4	-33	-35	-28	N/A
3/31/2019	4	-30	-33	-25	N/A
12/31/2018	3	-24	-27	-17	N/A
9/30/2018	1	-19	-27	-16	N/A
6/30/2018	0	-16	N/A	-13	N/A
3/31/2018	0	-13	N/A	-11	N/A
12/31/2017	0	-13	N/A	-12	N/A
9/30/2017	0	-13	N/A	-13	N/A
6/30/2017	1	-12	N/A	-14	N/A
3/31/2017	2	-12	N/A	-13	N/A
12/31/2016	2	-9	N/A	-10	N/A
9/30/2016	1	-8	N/A	-8	N/A
6/30/2016	1	-8	N/A	-7	N/A
3/31/2016	0	-8	N/A	-6	N/A
12/31/2015	0	-8	N/A	-6	N/A
9/30/2015	0	-7	N/A	-6	N/A
6/30/2015	0	-7	N/A	-5	N/A
3/31/2015	0	-7	N/A	-5	N/A
12/31/2014	1	-6	N/A	-4	N/A
9/30/2014	1	-6	N/A	-4	N/A
6/30/2014	1	-5	N/A	-4	N/A
3/31/2014	1	-5	N/A	-5	N/A
12/31/2013	1	-6	N/A	-5	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: SNZZ.F is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: SNZZ.F is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: SNZZ.F is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: SNZZ.F's revenue (71.9% per year) is forecast to grow faster than the US market (8.9% per year).

High Growth Revenue: SNZZ.F's revenue (71.9% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: SNZZ.F is forecast to be unprofitable in 3 years.

Senzime Future Growth

Future criteria checks 2/6

Key information

Recent future growth updates

Senzime AB (publ) Provides Earnings Guidance for 2025

Recent updates

Senzime AB (publ) to Report Q1, 2025 Results on May 07, 2025

Senzime Successfully Unveils Next-Generation TetraGraph Quantitative Train-Of-Four Monitor at ANESTHESI Technology 2024

Senzime to Launch Next-Generation Tetragraph System At Anesthesiology 2024 Conference

Senzime AB (publ.) Announces European Patent Office Issues New Patent Protecting Unique Capabilities of the Senzime TetraGraph System

Senzime AB (publ) to Report Q3, 2024 Results on Nov 06, 2024

Senzime AB (publ) Announces Board Changes

Senzime Announces New Clinical Study with the Tetragraph System Published in the British Journal of Anesthesia Open

Senzime AB (publ) to Report Fiscal Year 2023 Results on Feb 15, 2024

Senzime Launches Tetras Sensitive, the Market's First Sensor for Nemomuscular Monitoring of Patients with Sensitive Skin

Senzime AB (publ) Announces New Study Valued the Feasibility of TetraSens Pediatric Disposable Sensor

Senzime AB (publ) Presents Scientific Study at Euroanaesthesia 2023 and Validates New TetraGraph Electromyographic Detection Algorithm

Senzime AB (Publ) Appoints Philip Siberg as Chief Executive Officer

Senzime Receives Approval for Its Pediatric Sensor in Japan

Senzime AB (publ) to Report Q1, 2023 Results on May 05, 2023

Senzime AB (publ) to Report Fiscal Year 2022 Results on Feb 01, 2023

Senzime Receives First Contract for TetraSens Pediatric in the US

Senzime's TetraGraph supported by new European clinical guidelines for patient monitoring

Senzime AB (publ) Provides Earnings Guidance for 2025

Senzime AB (Publ) Announces Board Appointments

Senzime AB (publ) Receives FDA 510K-Clearance for New Disposable Sensor Intended for Monitoring of Children

Senzime AB (publ) Announces Launch of TetraGraph Xcom Interface to Electronic Medical Records

Senzime AB (publ) (OM:SEZI) entered into an agreement to acquire Respiratory Motion, Inc. for $44 million.

Senzime AB (Publ) Applies for FDA Approval for A New Single-Use Sensor for Children

Senzime Announces Anesthesia Patient Safety Foundation Recommends Use of A Quantitative Monitor Whenever A Neuromuscular Blocking Agent Is Administered

Senzime AB (Publ) Announces Japanese Study Confirms Tetragraph Monitor as a Better Indicator of Appropriate Reversal Dose of Sugammadex and Adequate Recovery of Neuromuscular Function Than Amg-Based Tof- Watch SX

Senzime AB (publ) Appoints Eva Walde as New Member of the Board of Directors

Senzime AB (publ) to Report Q3, 2021 Results on Nov 12, 2021

Senzime AB (publ) Gets US Patent for OnZurf Probe

Senzime Lands New Order from South Korea of SEK 1 Million

Senzime AB (publ) Announces Nomination Committee for 2021 Annual General Meeting

Senzime AB (Publ) Signs an Out-Licensing Agreement with the Moss S.P.A

Senzime AB (publ) Enters into an Exclusive Agreement with the Surgical Company

Senzime AB (Publ) Announces Management Changes

Senzime AB (publ) Receives Order from Switzerland

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies